Anti-Occludin / OCLN, clone MSVA-415M

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. OCLN antibody recognizes Occludin, a four-pass transmembrane tight junction protein encoded by the OCLN gene that plays a central role in epithelial and endothelial barrier integrity. OCLN Antibody for IHC is optimized for detecting Occludin expression in formalin-fixed, paraffin-embedded tissue specimens used in histopathology and barrier biology research. Occludin localizes primarily to the plasma membrane at tight junction complexes, where it forms continuous belt-like structures at apical cell-cell borders and interacts with claudins, TJP1, and the actin cytoskeleton to regulate paracellular permeability.Occludin antibody, also referred to in the literature as OCLN antibody and tight junction Occludin antibody, targets a structural component widely expressed in epithelial tissues including kidney, intestine, lung, and liver, as well as in endothelial barriers such as the blood-brain barrier. In tissue sections, Occludin is typically observed along apical lateral membranes of epithelial cells, highlighting tight junction architecture. Disruption, redistribution, or reduced expression of Occludin is commonly associated with barrier dysfunction in inflammatory, ischemic, and neoplastic conditions.Structurally, Occludin contains four transmembrane domains, two extracellular loops, and cytoplasmic N-terminal and C-terminal domains. The C-terminal cytoplasmic region is critical for tight junction assembly and interaction with scaffolding proteins such as TJP1. Post-translational modifications including phosphorylation regulate Occludin trafficking and junctional stability. Altered phosphorylation can result in internalization or fragmentation of tight junction complexes, contributing to increased permeability and epithelial injury.Changes in OCLN expression have been implicated in inflammatory bowel disease, acute lung injury, renal ischemia-reperfusion injury, and blood-brain barrier disruption. In cancer biology, remodeling of tight junctions and altered Occludin expression can influence tumor cell polarity and invasion. Because tight junction integrity is essential for maintaining tissue homeostasis, OCLN antibody remains an important tool for evaluating epithelial organization and barrier status in research settings.This mouse monoclonal antibody clone MSVA-415M targets Occludin for tissue-based research applications. By enabling visualization of OCLN expression patterns in formalin-fixed specimens, this Occludin antibody supports investigations into tight junction biology and epithelial barrier regulation at NSJ Bioreagents.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.